oropouch
caraparu
guama
guaroa
tacaiuma
virus
orthobunyaviru
genu
caus
human
febril
ill
andor
enceph
achiev
therapeut
agent
prevent
andor
treat
diseas
evalu
antivir
action
interferonalpha
orthobunyavirus
vitro
result
show
studi
orthobunyavirus
suscept
antivir
action
suscept
limit
depend
concentr
drug
treatment
period
vivo
result
demonstr
present
antivir
action
oropouch
guaroa
virus
use
prophylact
treatment
moreov
treatment
initi
h
infect
prevent
death
guaroa
viru
infectedmic
addit
mortal
mice
relat
migrat
replic
virus
brain
result
suggest
could
potenti
use
prevent
diseas
caus
oropouch
viru
prevent
andor
treatment
diseas
caus
guaroa
viru
oropouch
orov
caraparu
carv
guama
gmav
guaroa
grov
tacaiuma
tcmv
virus
belong
distinct
antigen
serogroup
genu
orthobunyaviru
bunyavirida
famili
virus
envelop
triseg
singlestrand
rna
genom
neg
ambisens
polar
replic
cytoplasm
bud
golgi
apparatu
elliot
et
al
upon
plasma
membran
goldsmith
et
al
orov
simbu
serogroup
transmit
mainli
bite
midg
culicoid
paraensi
associ
denguelik
acut
febril
ill
orov
fever
emerg
past
year
seriou
public
health
problem
tropic
subtrop
area
central
south
america
caus
least
report
outbreak
involv
correspond
author
tel
fax
email
address
pink
rpmfmrpuspbr
livonesi
zipmailcombr
mc
livonesi
half
million
peopl
watt
et
al
pinheiro
et
al
clinic
featur
orov
fever
includ
abrupt
onset
fever
chill
sever
headach
dizzi
myalgia
arthralgia
nausea
vomit
half
patient
recurr
symptom
within
day
becom
afebril
asept
mening
orov
report
outbreak
age
sex
appear
equal
suscept
infect
leduc
pinheiro
similarli
orov
carv
group
c
serogroup
gmav
guama
serogroup
grov
california
enceph
bunyamwera
serogroup
tcmv
anophel
serogroup
also
associ
febril
ill
human
virus
transmit
mosquito
caus
diseas
mainli
south
america
countri
brinton
et
al
tavaresneto
et
al
jonker
et
al
march
hetrick
travasso
da
rosa
et
al
iversson
et
al
iversson
antivir
therapi
avail
would
help
intervent
reduc
symptom
diseas
period
orov
fever
well
febril
ill
caus
orthobunyavirus
howev
moment
treatment
vaccin
viral
diseas
recent
studi
demonstr
virus
resist
antivir
action
ribavirin
broadspectrum
antivir
drug
livonesi
et
al
interferon
ifn
system
first
line
defens
viral
infect
mammal
system
abl
block
spread
viru
infect
bodi
sometim
expens
acceler
death
infect
cell
interferon
divid
two
type
type
type
ii
antivir
activ
sen
galligan
et
al
type
interferon
includ
secret
virusinfect
cell
exhibit
multipl
biolog
properti
includ
antiprolif
antivir
immunomodulatori
effect
platania
et
al
stark
et
al
goodbourn
et
al
type
ii
interferon
present
one
member
virusinduc
secret
activ
lymphocyt
nk
cell
show
antivir
activ
directli
induct
effector
molecul
eg
nitric
oxid
indirectli
enhanc
antigen
present
induct
apoptosi
boehm
et
al
due
antivir
properti
use
clinic
treat
chronic
infect
caus
hepat
b
c
virus
davi
et
al
mchutchison
et
al
treatment
infect
caus
hpv
sen
moreov
vitro
andor
vivo
experi
demonstr
abl
inhibit
replic
mani
virus
sandfli
fever
sicilian
cranc
et
al
dengu
diamond
et
al
sever
acut
respiratori
syndromerel
coronaviru
sar
cov
tan
et
al
et
al
galligan
et
al
vaccinia
liu
et
al
ebola
mahanti
et
al
thu
effort
character
antivir
agent
could
attenu
infect
caus
orov
carv
gmav
grov
tcmv
test
vitro
vivo
action
virus
oro
gma
gro
tcm
virus
kindli
suppli
dr
pedro
vasconcelo
dr
travasso
da
rosa
evandro
chaga
institut
brazilian
ministri
health
brazil
univers
texa
medic
branch
galveston
tx
usa
carv
kindli
suppli
dr
terezinha
lisieux
coimbra
adolpho
lutz
institut
paulo
brazil
viral
stock
obtain
brain
intracerebr
infect
newborn
mice
brain
mix
pb
dilut
wv
macer
centrifug
g
min
c
supernat
harvest
store
c
use
african
green
monkey
kidney
vero
cell
grown
minimum
essenti
medium
mem
cultilab
brazil
supplement
inactiv
mycoplasmafre
fetal
bovin
serum
fb
cultilab
brazil
lglutamin
sodium
bicarbon
roferon
hoffmannla
roch
usa
use
vitro
experi
recombin
murin
interferonalphaa
sigmaaldrich
st
loui
mo
usa
prepar
follow
instruct
manufactur
use
vivo
experi
swiss
newborn
mice
obtain
laboratori
anim
facil
univers
paulo
preto
brazil
mice
maintain
microisol
cage
anim
hous
facil
center
research
virolog
univers
paulo
preto
brazil
experi
approv
ethic
committe
vertebr
anim
experi
univers
paulo
vitro
antivir
evalu
done
plaqu
assay
livonesi
et
al
vero
cell
seed
plate
mem
fb
h
c
co
medium
remov
serial
dilut
viral
stock
dilut
mem
fb
ad
mlwell
quadrupl
cell
incub
h
c
subsequ
viral
inoculum
remov
ml
combin
vv
lowmeltingpoint
agaros
plu
mem
fb
ad
well
plate
incub
c
day
orov
gmav
day
carv
grov
day
tcmv
plaqu
visual
stain
naphtol
blue
black
solut
min
moren
et
al
preced
remov
agaros
plug
plaqu
count
invert
microscop
viru
titer
determin
log
pfu
ml
dilut
medium
ad
cell
h
h
viral
infect
comparison
viru
titer
obtain
nontreat
cell
cultur
done
result
plot
percentag
inhibit
plaqu
format
tabl
ad
cell
cultur
concentr
iu
ml
concentr
toxic
vero
cell
previous
describ
tan
et
al
frequent
advers
reaction
caus
administr
human
includ
fatigu
myalgia
arthralgia
headach
fever
chill
anorexia
nausea
vomit
diarrhea
abdomin
pain
usual
occur
patient
treat
high
dose
italian
cooper
studi
group
cml
schmutz
et
al
et
al
thu
paramet
chosen
evalu
toxic
mice
signific
weight
loss
mice
compar
placebotr
mice
dose
use
iu
ml
l
per
mouseday
mice
treat
intraperiton
ip
daili
day
anim
weight
determin
daili
concentr
chosen
iu
ml
well
toler
mice
present
increas
weight
similar
placebotr
mice
fig
furthermor
dose
iu
ml
approxim
highest
level
recombin
given
human
million
unit
daili
freireich
et
al
threedayold
swiss
mice
infect
ip
orov
ld
carv
ld
gmav
ld
grov
ld
tcmv
ld
volum
l
per
mous
mice
treat
ip
iu
ml
placebo
volum
l
per
mous
treatment
initi
h
h
infect
maintain
everi
day
anim
monitor
daili
mortal
suckl
mice
infect
ip
orov
carv
gmav
grov
tcmv
usual
die
develop
enceph
show
paralysi
forefoot
tremor
difficulti
eat
present
high
viral
titer
brain
day
death
consid
brain
princip
target
organ
viral
replic
viru
titer
obtain
organ
use
paramet
demonstr
efficaci
drug
thu
brain
mice
two
mice
per
group
taken
asept
day
infect
brain
mix
pb
dilut
wv
macer
centrifug
g
min
c
supernat
harvest
store
c
plaqu
assay
vero
cell
viru
titer
brain
express
log
pfu
ml
analysi
varianc
follow
parametr
tukeykram
test
use
vitro
experi
fisher
exact
test
use
vivo
experi
instat
softwar
graphpad
san
diego
ca
p
valu
less
consid
indic
statist
signific
firstli
vero
cell
treat
iu
ml
differ
period
cell
infect
orov
carv
gmav
grov
tcmv
tabl
show
abl
inhibit
replic
studi
orthobunyavirus
treatment
occur
either
h
h
infect
p
moreov
present
signific
inhibitori
activ
replic
gmav
p
tcmv
p
treatment
initi
h
infect
addit
significantli
inhibit
tcmv
replic
cell
treatment
initi
h
infect
p
result
show
present
inhibitori
effect
orov
carv
gmav
grov
tcmv
replic
effect
depend
time
treatment
next
verifi
whether
dose
lower
iu
ml
would
inhibitori
effect
replic
distinct
orthobunyaviru
thu
cell
treat
h
viral
infect
dose
iu
ml
medium
fig
show
concentr
iu
ml
abl
significantli
inhibit
carv
gmav
grov
tcmv
replic
orov
furthermor
concentr
iu
ml
produc
signific
inhibitori
effect
carv
grov
tcmv
replic
fig
suggest
antivir
effect
orthobunyavirus
also
depend
concentr
use
firstli
examin
whether
treatment
begin
day
viral
infect
would
effect
prevent
lethal
enceph
caus
orov
carv
gmav
grov
tcmv
intraperiton
administr
maximum
nontox
dose
iu
ml
fig
prevent
death
mice
infect
orov
grov
tabl
high
surviv
rate
associ
inhibit
viral
migrat
replic
brain
mice
fig
howev
treatment
carv
gmavor
tcmvinfect
mice
result
increas
surviv
prolong
mean
time
death
prevent
viru
replic
brain
anim
tabl
fig
respect
next
effect
administr
initi
h
infect
anim
orov
grov
analys
tabl
show
treatment
either
unabl
increas
surviv
time
inhibit
viral
replic
brain
tissu
mice
infect
orov
fig
hand
mice
surviv
rate
tabl
associ
inhibit
viral
replic
brain
tissu
mice
fig
treatment
initi
h
mice
infect
grov
unabl
inhibit
either
death
anim
viral
replic
brain
tabl
fig
respect
fig
orovor
grovinfect
mice
show
viru
replic
brain
treatment
initi
h
infect
group
sixteen
swiss
mice
infect
ip
orov
carv
gmav
grov
tcmv
treat
ip
iu
ml
placebo
mous
brain
two
mice
per
group
taken
day
infect
viru
titer
brain
measur
plaqu
assay
scale
bar
repres
mean
pfu
ml
similar
result
obtain
second
experi
h
orov
grov
b
h
grov
mean
time
death
b
p
fisher
exact
test
fig
grovinfect
mice
show
viru
replic
brain
treatment
initi
h
infect
group
sixteen
swiss
mice
infect
ip
orov
grov
treat
iu
ml
placebo
mous
brain
two
mice
per
group
taken
day
infect
viru
titer
brain
measur
plaqu
assay
scale
bar
repres
mean
pfu
ml
similar
result
obtain
second
experi
fig
treatment
initi
h
infect
inhibit
replic
grov
brain
tissu
mice
group
nine
swiss
mice
infect
grov
treat
iu
ml
placebo
treatment
initi
h
infect
mous
brain
two
mice
per
group
taken
day
infect
viru
titer
brain
measur
plaqu
assay
scale
bar
repres
mean
pfu
ml
similar
result
obtain
second
experi
result
also
show
vivo
antivir
activ
orov
grov
depend
time
treatment
studi
evalu
vitro
vivo
antivir
activ
orov
carv
gmav
grov
tcmv
signific
antivir
effect
vitro
studi
orthobunyavirus
antivir
action
observ
depend
administr
time
tabl
concentr
drug
fig
vivo
experi
confirm
antivir
activ
orov
grov
carv
gmav
tcmv
antivir
activ
depend
administr
period
drug
tabl
antivir
effect
observ
vivo
relat
abil
inhibit
viral
replic
brain
tissu
infect
mice
antivir
action
exogen
observ
vitro
probabl
due
abil
induc
antivir
state
cell
secret
protein
ultim
inhibit
viral
replic
instanc
dsrnadepend
protein
kinas
pkr
lead
phosphoryl
consequ
blockad
translat
cellular
viral
mrna
oligoadenyl
synthetas
oa
also
activ
viral
dsrna
produc
oligoadenyl
turn
activ
rnase
l
result
degrad
viral
host
rna
mx
protein
gtpase
dynamin
famili
whose
mechan
action
function
await
elucid
stetson
medzhitov
similarli
antivir
effect
observ
vivo
administr
exogen
might
either
due
abovement
cellintrins
mechan
cytokin
action
type
ifn
immun
system
fact
type
ifn
abl
enhanc
express
mhc
class
protein
cell
therebi
promot
cell
respons
goodbourn
et
al
moreov
type
ifn
play
essenti
role
differenti
function
effector
cell
stetson
medzhitov
type
ifn
also
abl
enhanc
cytotox
nk
cell
upregul
level
perforin
stimul
prolifer
nk
cell
limit
degre
stetson
medzhitov
ordinarili
nk
cell
elimin
infect
cell
defend
host
intracellular
infect
stetson
medzhitov
howev
mechan
exogen
perform
function
analys
present
studi
vitro
vivo
result
show
abl
prevent
viral
replic
limit
manner
exert
antivir
effect
administr
earli
high
dose
suggest
orov
carv
gmav
grov
tcmv
present
escap
mechan
antivir
action
resist
ifn
system
previous
describ
three
member
bunyavirida
famili
carv
brinton
et
al
rift
valey
fever
viru
bouloy
et
al
bunyamwera
viru
weber
et
al
et
al
brinton
et
al
corrobor
result
obtain
us
observ
carv
resist
antivir
action
immmunomodul
howev
escap
mechan
carv
studi
author
rift
valey
fever
bunyamwera
virus
present
resist
ifn
system
associ
nonstructur
protein
nss
encod
viral
replic
protein
show
abl
block
product
inhibit
transcript
factor
bouloy
et
al
weber
et
al
addit
recent
studi
demonstr
nss
protein
also
abl
inhibit
ifn
respons
interact
compon
mediat
protein
complex
necessari
mrna
product
et
al
studi
cell
mice
receiv
high
dose
exogen
possibl
inhibit
product
endogen
orthobunyavirus
would
suffici
block
antivir
effect
deriv
exogen
moreov
known
vero
cell
ifn
gene
defici
thu
unabl
express
endogen
type
ifn
mosca
pitha
howev
ifndepend
pathway
function
activ
exogen
provid
ifn
mosca
pitha
thu
possibl
studi
orthobunyavirus
present
escap
mechan
similar
recent
describ
bunyamwera
viru
et
al
abl
inhibit
respons
produc
ifn
associ
cell
surfac
receptor
would
interest
elucid
escap
mechan
use
differ
bunyavirus
especi
etiolog
relat
human
diseas
import
mention
cytokin
test
studi
part
larg
group
exist
foster
finter
yeow
et
al
therefor
affirm
whether
would
present
similar
antivir
activ
observ
instanc
tan
et
al
evalu
vitro
antivir
activ
four
type
roferon
intron
wellferon
alferon
sar
coronaviru
sarscov
observ
two
wellferon
alferon
abl
inhibit
cytophat
effect
caus
viru
vero
cell
cultur
mechan
explain
differ
activ
unknown
may
suppos
could
relat
distinct
sourc
prepar
deriv
human
lymphoblastoid
leukocyt
cell
prepar
recombinantli
produc
escherichia
coli
mammalian
cell
cultur
foster
finter
particular
use
experi
roferon
produc
e
coli
conclus
result
demonstr
present
vitro
antivir
activ
carv
gmav
tcmv
activ
limit
confirm
vivo
experi
therefor
could
consid
suitabl
therapeut
drug
ill
caus
virus
howev
present
vitro
vivo
prophylact
antivir
activ
orov
grov
also
show
therapeut
antivir
action
grov
thu
could
potenti
use
prevent
diseas
caus
oropouch
viru
prevent
andor
treatment
diseas
caus
guaroa
viru
mainli
epidem
occurr
laboratori
accid
